Abstract:After the start of the COVID-19 pandemic and its spread across the world, countries have adopted containment measures to stop its transmission, limit fatalities, and relieve hospitals from straining and overwhelming conditions imposed by the virus. Many countries implemented social distancing and lockdown strategies that negatively impacted their economies and the psychological wellbeing of their citizens, even though they contributed to saving lives. Recently approved and available, COVID-19 vaccines can provide a really viable and sustainable option for controlling the pandemic. However, their uptake represents a global challenge due to vaccine hesitancy and logistic-organizational hurdles that have made its distribution stagnant in several developed countries despite several appeals by the media, policy- and decision-makers, and community leaders. Vaccine distribution is also a concern in developing countries, where there is a scarcity of doses. The objective of the present study was to set up a metric to assess vaccination uptake and identify national socio-economic factors influencing this indicator. We conducted a cross-country study. We first estimated the vaccination uptake rate across countries by fitting a logistic model to reported daily case numbers. Using the uptake rate, we estimated the vaccine roll-out index. Next, we used Random Forest, an "off-the-shelf" machine learning algorithm, to study the association between vaccination uptake rate and socio-economic factors. We found that the mean vaccine roll-out index is 0.016 (standard deviation 0.016), with a range between 0.0001 (Haiti) and 0.0829 (Mongolia). The top four factors associated with the vaccine roll-out index are the median per capita income, human development index, percentage of individuals who have used the internet in the last three months, and health expenditure per capita. The still-ongoing COVID-19 pandemic has shed light on the disparity in vaccine adoption across low- and high-income countries, which represents a global public health challenge. We must pave the way for universal access to vaccines and other approved treatments, regardless of demographic structures and underlying health conditions. Income disparity remains, instead, an important cause of vaccine inequity, which restricts the functioning of the global vaccine allocation framework and, thus, the ending of the pandemic. Stronger mechanisms are needed to foster countries' political willingness to promote vaccine and drug access equity in a globalized society where future pandemics and other global health crises can be anticipated.

Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models

Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future

Can we move beyond vaccine apartheid? Examining the determinants of the COVID-19 vaccine gap

International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility

COVID-19 vaccine access in Africa: Global distribution, vaccine platforms, and challenges ahead

Equitable access to COVID-19 vaccines makes a life-saving difference to all countries

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

COVID-19 Vaccination and Public Health: Addressing Global, Regional, and Within-Country Inequalities

Factors, enablers and challenges for COVID-19 vaccine development

Assessing Inequities in COVID-19 Vaccine Roll-Out Strategy Programs: A Cross-Country Study Using a Machine Learning Approach

Reimagining Vaccine Access for Health Equity

Global inequities in access to COVID-19 health products and technologies: A political economy analysis

Pursuing equitable access to vaccines for the next epidemic

Comparing research and development, launch, and scale up timelines of 18 vaccines: lessons learnt from COVID-19 and implications for other infectious diseases

International Efforts and Next Steps to Advance COVID-19 Vaccines Research and Production in Low- and Middle-Income Countries

COVID-19 vaccine inequity in African low-income countries

Using absolute risk reduction to guide the equitable distribution of COVID-19 vaccines

Pharmaceutical Industry’s Engagement in the Global Equitable Distribution of COVID-19 Vaccines: Corporate Social Responsibility of EUL Vaccine Developers

How Enlightened Self-Interest Guided Global Vaccine Sharing Benefits All: A Modeling Study

Solidarity across borders: A pragmatic need for global COVID‐19 vaccine equity

Global Disparities in Access to Vaccine Clinical Trials: A Review of the Literature